Notizie AIOM – anno XVII n. 741
NICE Approves Maintenance Rucaparib for Relapsed Ovarian Cancer
Oct 11, 2019 - The UK’s National Institute for Health and Care Excellence (NICE) has approved rucaparib for the maintenance treatment of patients with relapsed ovarian, fallopian tube, or peritoneal cancer that has responded to platinum-based chemotherapy. The decision ...Leggi tutto
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
Patients with metastatic pancreatic cancer (mPC) often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, Phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase ...Leggi tutto
2019 Nobel Prize in Physiology or Medicine Announced
Oct 7, 2019 - Today, the Nobel Assembly at Karolinska Institutet announced its decision to award the 2019 Nobel Prize in Physiology or Medicine jointly to William G. Kaelin Jr, MD; Sir Peter J. Ratcliffe, FRS; and Gregg L. Semenza, MD, PhD, for their discoveries of how cells ...Leggi tutto
FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
Oct 8, 2019 - The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $15 million over the next four years to enhance the development of medical products for patients with rare diseases. The grants ...Leggi tutto
FDA awards two grants for natural history studies in rare diseases
Oct 8, 2019 - The U.S. Food and Drug Administration today announced it has awarded two new research grants for natural history studies in rare diseases. The FDA is providing over $4.1 million over the next four years to fund these studies. Information from natural history ...Leggi tutto
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Data are limited regarding the use of poly(adenosine diphosphate -ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovarian carcinoma. In an international, phase ...Leggi tutto